Janus Henderson Group PLC Tyra Biosciences, Inc. Call Options Transaction History
Janus Henderson Group PLC
- $188 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TYRA
# of Institutions
112Shares Held
49.9MCall Options Held
36.6KPut Options Held
1.1K-
Ra Capital Management, L.P. Boston, MA10.6MShares$140 Million2.39% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.18MShares$55.1 Million97.27% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$53.8 Million89.47% of portfolio
-
Nextech Invest Ag4.06MShares$53.5 Million10.51% of portfolio
-
Bvf Inc San Francisco, CA3.94MShares$52 Million2.05% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $554M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...